Annovis Bio (ANVS) Stock Price, News & Analysis

Company Overview

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Key Stats

• Today's Range: $2.22 to $2.34
• 50-Day Range: $2.18 to $2.94
• 52-Week Range: $1.11 to $10.54
• Volume: 169,313 shs
• Average Volume: 222,705 shs
• Market Capitalization: $44.65 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.33
• Consensus Rating: Moderate Buy

Annovis Bio Stock Analysis - MarketRank™

Annovis Bio scored higher than 54% of companies evaluated by MarketBeat, and ranked 618th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Annovis Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

Annovis Bio has a consensus price target of $17.33, representing about 656.6% upside from its current price of $2.29.

Amount of Analyst Coverage

Annovis Bio has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Annovis Bio are expected to grow in the coming year, from ($2.19) to ($1.68) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Annovis Bio is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Annovis Bio is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Annovis Bio has a P/B Ratio of 3.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.59% of the outstanding shares of Annovis Bio have been sold short.

Short Interest Ratio / Days to Cover

Annovis Bio has a short interest ratio ("days to cover") of 4.4.

Change versus previous month

Short interest in Annovis Bio has recently decreased by 14.61%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Annovis Bio does not currently pay a dividend.

Dividend Growth

Annovis Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.59% of the outstanding shares of Annovis Bio have been sold short.

Short Interest Ratio / Days to Cover

Annovis Bio has a short interest ratio ("days to cover") of 4.4.

Change versus previous month

Short interest in Annovis Bio has recently decreased by 14.61%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.49

News Sentiment

Annovis Bio has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Annovis Bio this week, compared to 3 articles on an average week.

MarketBeat Follows

1 people have added Annovis Bio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Annovis Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

20.80% of the stock of Annovis Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 15.83% of the stock of Annovis Bio is held by institutions.

ANVS Stock Analysis - Frequently Asked Questions

How have ANVS shares performed this year?

Annovis Bio's stock was trading at $5.03 at the beginning of the year. Since then, ANVS stock has decreased by 54.5% and is now trading at $2.2910.

How were Annovis Bio's earnings last quarter?

Annovis Bio, Inc. (NYSE:ANVS) issued its earnings results on Tuesday, August, 12th. The company reported ($0.32) EPS for the quarter, topping analysts' consensus estimates of ($0.36) by $0.04.

When did Annovis Bio IPO?

Annovis Bio (ANVS) raised $10 million in an initial public offering (IPO) on Wednesday, January 29th 2020. The company issued 1,400,000 shares at $6.00-$8.00 per share. ThinkEquity (a division of Fordham Financial Management, Inc. ) acted as the underwriter for the IPO.

Who are Annovis Bio's major shareholders?

Annovis Bio's top institutional shareholders include Geode Capital Management LLC (0.94%), Marshall Wace LLP (0.47%), Simplex Trading LLC and Jane Street Group LLC (0.12%).
View institutional ownership trends.

How do I buy shares of Annovis Bio?

Shares of ANVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Annovis Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Annovis Bio investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 9/06/2025
• Next Earnings (Estimated): 11/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:ANVS
• CIK: 1477845
• Web: www.annovisbio.com
• Phone: 610-727-3913
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Annovis Bio: $17.33
• High Price Target: $25.00
• Low Price Target: $10.00
• Potential Upside/Downside: +656.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.59 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -206.01%
• Return on Assets: -158.26%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.65
• Quick Ratio: 7.65

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.67 per share
• Price / Book: 3.42

Miscellaneous

• Outstanding Shares: 19,490,000
• Free Float: 15,433,000
• Market Cap: $44.65 million
• Optionable: Optionable
• Beta: 1.65